ReRad_1st patient.png

Photo: Niels Aage Skovbo


The first patient is now included in the ReRad II protocol that will examine the effect of doseescalated proton therapy for recurrences in rectal cancer patients.

The ReRad II protocol is expected to enrol up to 120 patients in Denmark. The trial will evaluate the effect of doseescalated proton therapy on disease control and toxicities and will also include quality of life assessment.

- These patients have previously gone through radiotherapy and surgery, and optimal treatment is complex and based on multidisciplinary collaboration and patient involvement. The aim of this study is to improve outcome for these patients with acceptable toxicity and quality of life, explains PI, Camilla Jensenius Skovhus Kronborg, Specialty Registrar, PhD, the Danish Centre for Particle Therapy.